JP2007530584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530584A5 JP2007530584A5 JP2007505204A JP2007505204A JP2007530584A5 JP 2007530584 A5 JP2007530584 A5 JP 2007530584A5 JP 2007505204 A JP2007505204 A JP 2007505204A JP 2007505204 A JP2007505204 A JP 2007505204A JP 2007530584 A5 JP2007530584 A5 JP 2007530584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- cancer
- integrin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 27
- 102000004965 antibodies Human genes 0.000 claims 20
- 108090001123 antibodies Proteins 0.000 claims 20
- 210000004027 cells Anatomy 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 102000006495 integrins Human genes 0.000 claims 7
- 108010044426 integrins Proteins 0.000 claims 7
- 229920000136 polysorbate Polymers 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 4
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- 229950008882 Polysorbate Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000008808 fibrosarcoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (22)
- 患者において癌細胞の増殖を阻害するための組成物であって、該癌細胞は、該癌細胞の表面上にα５β１インテグリンを発現し、該組成物は、以下：
約１．０ｍｇ／ｍＬ〜１５ｍｇ／ｍＬの抗α５β１抗体；
約２２ｍＭ〜２７ｍＭのクエン酸塩；
約１４５ｍＭ〜１６５ｍＭの塩化ナトリウム；および
約０．０４％〜０．０６％のポリソルベート（ＴＷＥＥＮ（登録商標））８０
を含み、ｐＨが約５．５〜７．５である治療有効量の液体処方物を含む、組成物。 - 前記抗体が、α５β１インテグリンの少なくとも一つの生物活性を中和する、請求項１に記載の組成物。
- 前記抗α５β１抗体が、Ｍ２００抗体と同じα５β１インテグリンのエピトープに結合する、請求項１に記載の組成物。
- 前記抗α５β１抗体が、前記細胞表面上に発現したα５β１インテグリンへのＭ２００の結合を競合的に阻害する、請求項１に記載の組成物。
- 前記抗α５β１抗体が、Ｍ２００、Ｆ２００およびＩＩＡ１からなる群から選択される、請求項１に記載の組成物。
- 前記抗体が、前記癌細胞表面上のα５β１インテグリンへの二次抗体の結合を競合的に阻害し、ここで該二次抗体は、配列番号２、配列番号４、配列番号６および配列番号８から選択されるアミノ酸配列を含む、請求項１に記載の組成物。
- 前記治療上有効な用量が約１０ｍｇ／ｋｇである、請求項１に記載の組成物。
- 前記癌細胞が、乳癌細胞、肺癌細胞、転移性メラノーマ細胞、膵臓癌細胞および腎細胞癌腫細胞からなる群から選択される、請求項１に記載の組成物。
- 前記癌が、腎細胞癌腫または転移性メラノーマである、請求項１に記載の組成物。
- 前記抗体と連続的にか、または該抗体併用するかのいずれかで前記患者に投与される化学療法剤をさらに含む、請求項１に記載の組成物。
- α５β１を発現する癌について、被験体を処置するための組成物であって、該被験体は腫瘍をまだ発症しておらず、該組成物は、以下：
約１．０ｍｇ／ｍＬ〜１５ｍｇ／ｍＬの抗α５β１抗体；
約２２ｍＭ〜２７ｍＭのクエン酸塩；
約１４５ｍＭ〜１６５ｍＭの塩化ナトリウム；および
約０．０４％〜０．０６％のポリソルベート（ＴＷＥＥＮ（登録商標））８０
を含み、ｐＨが約５．５〜７．５である治療有効量の液体処方物を含む、組成物。 - 前記抗体が、Ｍ２００と同じα５β１インテグリンのエピトープに結合する、請求項１１に記載の組成物。
- 前記抗体が、前記癌細胞表面に発現したα５β１インテグリンへのＭ２００の結合を競合的に阻害する、請求項１１に記載の組成物。
- 前記癌が、膀胱癌、乳癌、結腸癌、線維肉腫、肺癌、転移性メラノーマ、膵臓癌、前立腺癌、卵巣癌、腎細胞癌腫および脾臓癌からなる群から選択される、請求項１１に記載の組成物。
- 前記癌が、腎細胞癌腫または転移性メラノーマである、請求項１１に記載の組成物。
- 前記治療有効量が、約１０ｍｇ／ｋｇである、請求項１１に記載の組成物。
- 前記抗体と連続的にか、または前記抗体と併用してかのいずれかで前記被験体に投与される化学療法剤をさらに含む、請求項１１に記載の組成物。
- 約１．０ｍｇ／ｍＬ〜１５ｍｇ／ｍＬの抗α５β１抗体；
約２２ｍＭ〜２７ｍＭのクエン酸塩；
約１４５ｍＭ〜１６５ｍＭの塩化ナトリウム；および
約０．０４％〜０．０６％のポリソルベート（ＴＷＥＥＮ（登録商標））８０
を含有し、ｐＨが約５．５〜７．５である液体処方物を含む、薬学的組成物。 - 前記抗α５β１抗体の濃度が、約１０ｍｇ／ｍＬである、請求項１８に記載の薬学的組成物。
- 前記抗α５β１抗体が、Ｍ２００、Ｆ２００およびＩＩＡ１からなる群より選択される、請求項１８に記載の薬学的組成物。
- 前記抗α５β１抗体がＭ２００である、請求項１８に記載の薬学的組成物。
- 前記組成物が化学療法剤をさらに含む、請求項１８に記載の薬学的組成物。
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55642104P | 2004-03-24 | 2004-03-24 | |
| US55642204P | 2004-03-24 | 2004-03-24 | |
| US60/556,421 | 2004-03-24 | ||
| US60/556,422 | 2004-03-24 | ||
| US62504904P | 2004-11-03 | 2004-11-03 | |
| US60/625,049 | 2004-11-03 | ||
| US65109805P | 2005-02-07 | 2005-02-07 | |
| US60/651,098 | 2005-02-07 | ||
| US65751405P | 2005-02-28 | 2005-02-28 | |
| US60/657,514 | 2005-02-28 | ||
| PCT/US2005/009939 WO2005092073A2 (en) | 2004-03-24 | 2005-03-24 | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530584A JP2007530584A (ja) | 2007-11-01 |
| JP2007530584A5 true JP2007530584A5 (ja) | 2008-05-08 |
| JP4857259B2 JP4857259B2 (ja) | 2012-01-18 |
Family
ID=35056776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505204A Expired - Fee Related JP4857259B2 (ja) | 2004-03-24 | 2005-03-24 | 癌細胞増殖を阻害するための抗α５β１抗体の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7662384B2 (ja) |
| EP (1) | EP1755659B1 (ja) |
| JP (1) | JP4857259B2 (ja) |
| KR (1) | KR20070009637A (ja) |
| AT (1) | ATE531388T1 (ja) |
| AU (1) | AU2005226736B2 (ja) |
| BR (1) | BRPI0509177A (ja) |
| CA (1) | CA2560508A1 (ja) |
| DK (1) | DK1755659T3 (ja) |
| ES (1) | ES2376556T3 (ja) |
| HK (1) | HK1101348A1 (ja) |
| IL (1) | IL178042A (ja) |
| NO (1) | NO20064794L (ja) |
| NZ (1) | NZ549893A (ja) |
| WO (1) | WO2005092073A2 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| NZ571068A (en) * | 2006-03-21 | 2012-06-29 | Genentech Inc | An antibody that can bind human alpha5beta1 |
| WO2007114851A1 (en) * | 2006-04-04 | 2007-10-11 | The Board Of Trustees Of The University Of Illinois | Methods and compositions to induce cell death of invasive tumors |
| CA2652886A1 (en) * | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity |
| US20100150931A1 (en) * | 2006-11-22 | 2010-06-17 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| MX2010000997A (es) * | 2007-07-27 | 2010-03-31 | Facet Biotech Corp | Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b). |
| CL2008002856A1 (es) | 2007-09-26 | 2009-01-16 | Genentech Inc | Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1). |
| AU2009212442C1 (en) * | 2008-02-05 | 2014-07-17 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| TWI504409B (zh) * | 2009-03-25 | 2015-10-21 | Genentech Inc | 新穎抗－α５β１抗體及其用途 |
| US20110319335A1 (en) | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| PE20141413A1 (es) | 2011-10-25 | 2014-10-25 | Onclave Therapeutics Ltd | Formulaciones de anticuerpo y metodos |
| US8946159B2 (en) | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| NO2760138T3 (ja) | 2012-10-01 | 2018-08-04 | ||
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704366A (en) * | 1984-06-22 | 1987-11-03 | Bio-Rad Laboratories, Inc. | Process for binding IgG to protein A |
| JPS61134325A (ja) * | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4801687A (en) * | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3854306B2 (ja) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
| AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| NZ249677A (en) * | 1992-02-19 | 1996-08-27 | Schering Corp | Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE250138T1 (de) | 1992-10-29 | 2003-10-15 | Univ Australian | Angiogenese-inhibierende antikörper |
| US5536814A (en) * | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP0704920B1 (en) * | 1994-09-21 | 2000-04-19 | Matsushita Electric Industrial Co., Ltd. | Solid-state lithium secondary battery |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| WO1997033887A1 (en) | 1996-03-15 | 1997-09-18 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| US5922676A (en) * | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
| US5846536A (en) | 1996-10-04 | 1998-12-08 | The Regents Of The University Of California | Restoration of normal phenotype in cancer cells |
| WO1998032771A1 (fr) | 1997-01-29 | 1998-07-30 | Toray Industries, Inc. | Proteines chimeres, complexes heterodimeres de ces proteines et substituant de plaquette |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AU2444899A (en) * | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| CA2330277A1 (en) | 1998-04-27 | 1999-11-04 | Sidney Kimmel Cancer Center | Reduced complexity nucleic acid targets and methods of using same |
| WO1999058139A2 (en) * | 1998-05-08 | 1999-11-18 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| AU6902200A (en) | 1999-08-11 | 2001-03-05 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| WO2001053297A1 (en) | 2000-01-20 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2001053262A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US20040259152A1 (en) * | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
| JP2004531249A (ja) | 2001-02-14 | 2004-10-14 | プロテイン デザイン ラブス インコーポレイティド | 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法 |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| JP4741242B2 (ja) * | 2002-11-26 | 2011-08-03 | アボット バイオセラピューティクス コーポレイション | 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体 |
| US20050002930A1 (en) * | 2003-04-03 | 2005-01-06 | Johnson Dale E. | Methods of production and use of anti-integrin antibodies for the control of tissue granulation |
| KR20060080535A (ko) * | 2003-05-14 | 2006-07-10 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
-
2005
- 2005-03-24 KR KR1020067021955A patent/KR20070009637A/ko not_active Application Discontinuation
- 2005-03-24 EP EP05744016A patent/EP1755659B1/en active Active
- 2005-03-24 JP JP2007505204A patent/JP4857259B2/ja not_active Expired - Fee Related
- 2005-03-24 US US11/090,331 patent/US7662384B2/en not_active Expired - Fee Related
- 2005-03-24 NZ NZ549893A patent/NZ549893A/en not_active IP Right Cessation
- 2005-03-24 ES ES05744016T patent/ES2376556T3/es active Active
- 2005-03-24 CA CA002560508A patent/CA2560508A1/en not_active Abandoned
- 2005-03-24 WO PCT/US2005/009939 patent/WO2005092073A2/en active Application Filing
- 2005-03-24 AT AT05744016T patent/ATE531388T1/de active
- 2005-03-24 AU AU2005226736A patent/AU2005226736B2/en not_active Ceased
- 2005-03-24 DK DK05744016.6T patent/DK1755659T3/da active
- 2005-03-24 BR BRPI0509177-2A patent/BRPI0509177A/pt not_active IP Right Cessation
-
2006
- 2006-09-12 IL IL178042A patent/IL178042A/en not_active IP Right Cessation
- 2006-10-23 NO NO20064794A patent/NO20064794L/no not_active Application Discontinuation
-
2007
- 2007-06-08 HK HK07106150.6A patent/HK1101348A1/xx not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/642,687 patent/US20100291111A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530584A5 (ja) | ||
| RU2007127842A (ru) | Антитела против ангиопоэтина-2 и их применение | |
| RU2019101632A (ru) | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента | |
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Lippert III | Vascular disrupting agents | |
| Scott et al. | A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer | |
| Cobleigh et al. | A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer | |
| Han et al. | Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient | |
| Shin et al. | Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma | |
| Cao et al. | Targeting super-enhancer-driven oncogenic transcription by CDK7 inhibition in anaplastic thyroid carcinoma | |
| Chaudhry et al. | Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer | |
| JP2009500431A5 (ja) | ||
| JP2009510165A5 (ja) | ||
| Persson et al. | First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts | |
| JP2007504280A5 (ja) | ||
| JP2009539380A5 (ja) | ||
| Wichert et al. | Targeting carbonic anhydrase IX with small organic ligands | |
| US11266639B2 (en) | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers | |
| JP2011506274A5 (ja) | ||
| WO2009114809A1 (en) | Therapies for cancer using isotopically substituted lysine | |
| CN104262460A (zh) | 一种靶向人乳腺癌细胞的多肽及其应用 | |
| JP2010534685A (ja) | チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ | |
| JP2008154589A5 (ja) | ||
| AU2003229431B2 (en) | Method for reducing pain using oncolytic viruses | |
| JP2011504361A (ja) | 肝細胞癌細胞に特異的なペプチドおよびその適用 |